| 1 |
33814929 | Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib. | 2021 |
1 |
| 2 |
35070994 | Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology. | 2021 |
3 |
| 3 |
32957736 | Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review. | 2020 Sep 17 |
1 |
| 4 |
29883837 | Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. | 2018 Sep |
1 |
| 5 |
27575422 | High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer. | 2017 Jan |
2 |
| 6 |
27094798 | Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. | 2016 Jul |
4 |
| 7 |
27544536 | Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy. | 2016 Oct |
3 |
| 8 |
27611848 | Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site. | 2016 Oct 2 |
2 |
| 9 |
27738334 | Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement. | 2016 Nov 15 |
4 |
| 10 |
25665893 | Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer. | 2015 Sep |
1 |
| 11 |
23788756 | The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. | 2013 Sep |
1 |
| 12 |
23810364 | A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements. | 2013 Sep |
1 |